RENB (Renovaro) GF Score : 39/100 (As of Apr. 05, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Renovaro GF Score?

Renovaro has the GF Score of 39, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 8/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Renovaro might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Renovaro's GF Score

For the Biotechnology subindustry, Renovaro's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renovaro's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's GF Score distribution charts can be found below:

* The bar in red indicates where Renovaro's GF Score falls into.

Save Embed

;

Save Embed

;

Renovaro (NAS:RENB) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Renovaro GF Score Related Terms

Thank you for viewing the detailed overview of Renovaro's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovaro Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

2Q5:Germany

Address

2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067

Website

https://www.renovarogroup.com

Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.

Executives

Anderson Wittekind William	10 percent owner	8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leni Boeren	director	2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks	director	CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard	10 percent owner	VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette	officer: Executive Vice President	2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu	10 percent owner	2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev	director, 10 percent owner	FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler	other: Former director see note below	330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol	director	606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen	director	STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche	officer: Chief Financial Officer	318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne	director	NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Leire, Eric Jean Marie	director, officer: CEO; President	C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060